We benefit greatly from ongoing discussions of our data with the medical and public health communities.
Our posters facilitate these discussions by highlighting key data for presentation at global conferences.
VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at ID Week 2020™
VBI Vaccines Announces Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020
VBI Vaccines Announces Data from VBI-1901 Presented at AACR 2020: Partial Response Observed, Promising Biomarker Strategy Identified
VBI Vaccines Presents Early GBM Tumor Response and Immunologic Data from Part B of Ongoing Phase 1/2a Study of VBI-1901 at the 2019 SNO Annual Meeting
VBI Vaccines Announces Late-Breaker Poster Presentation at The Liver Meeting® 2019
VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
VBI Vaccines Announces Late-Breaking Poster Presentation at EASL 2019
VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
VBI Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference
